References
- Martei, Y.M., et al., Breast cancer in low-and middle-income countries: why we need pathology capability to solve this challenge. Clinics in laboratory medicine, 2018. 38(1): p. 161–173.
- Arnold, M., et al., Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 2022. 66: p. 15–23.
- Lou, M.W., et al., Linking physical activity to breast cancer via inflammation, Part 2: The effect of inflammation on breast cancer risk. Cancer Epidemiology, Biomarkersa & Prevention, 2023. 32(5): p. 597–605.
- Jayashree, V. and M. Velraj, Breast Cancer and various Prognostic Biomarkers for the diagnosis of the disease: A Review. Research Journal of Pharmacy and Technology, 2017. 10(9): p. 3211–3216.
- Asaad, R.A. and S.S. Abdullah, Breast cancer subtypes (BCSs) classification according to hormone receptor status: Identification of patients at high risk in Jableh-Syria. Research Journal of Pharmacy and Technology, 2018. 11(8): p. 3703–3710.
- Luo, C., et al., Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer. The Breast, 2022. 63: p. 24–28.
- Guo, Y.-Z., et al., Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pacific Journal of Cancer Prevention, 2013. 14(1): p. 243–248.
- Asaad, R.A., Hormone receptor status and its relation to C-reactive protein and other prognostic factors in breast cancer in Jableh-Syria. Research Journal of Pharmacy and Technology, 2017. 10(9): p. 3003–3010.
- Allison, K.H., et al., Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. 2020.
- Kadi, M.S., et al., Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center. Cureus, 2023. 15(7).
- Aleskandarany, M.A., et al., Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology, 2018. 85(1–2): p. 23–34.
- Makhlouf, S., et al., The clinical and biological significance of estrogen receptor-low positive breast cancer. Modern Pathology, 2023. 36(10): p. 100284.
- Asaad, R.A., Lymph Node Ratio (LNR) as a predictive factor in addition to pNstaging in Syrian-breast cancer patients at diagnosis. Research Journal of Pharmacy and Technology, 2018. 11(3): p. 933–940.
- Łukasiewicz, S., et al., Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 2021. 13(17): p. 4287.
- Puhalla, S., S. Bhattacharya, and N.E. Davidson, Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol, 2012. 6(2): p. 222–36.
- Reinert, T., et al., Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Frontiers in Endocrinology, 2022. 13: p. 1015388.
- Moldoveanu, D., et al., Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1–10%) Breast Cancer. Annals of surgical oncology, 2023. 30(11): p. 6475–6483.
- Paakkola, N.-M., et al., The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. ESMO open, 2021. 6(6): p. 100289.